about
A role for glucagon-like peptide-1 in the central regulation of feedingSibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide YEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Obesity and diabetes.Leptin and the control of obesity.The importance of weight management in type 2 diabetes mellitus.Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.1,25-dihydroxyvitamin D3 protects against macrophage-induced activation of NFκB and MAPK signalling and chemokine release in human adipocytes.Hypothalamic obesity in humans: what do we know and what can be done?Sleep disordered breathing--a new component of syndrome x?Neuropeptides and appetite control.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialSodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.Obesity and type-2 diabetes in the elderly.Clinical evaluation of anti-obesity drugs.Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study.Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment.Night eating syndrome: implications for severe obesityGut peptides and the regulation of appetite.Thiazolidinediones, insulin resistance and obesity: Finding a balance.Treatment strategies for obesity.The importance of free fatty acids in the development of Type 2 diabetes.Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatmentExposure-response analyses of liraglutide 3.0 mg for weight management.Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.Modern management of obesity.SPARC: a key player in the pathologies associated with obesity and diabetes.Vitamin D signalling in adipose tissue.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Liraglutide in the treatment of obesity.The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome.A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.Impact of bariatric surgery on physical functioning in obese adults.Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose CotEnergy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
P50
Q24314317-54CF3F2A-94F3-427A-8425-D10EE562D08FQ28363106-FA1C5AF5-24F3-4FDD-88CF-5C155DED8114Q33845734-38330527-620F-4716-B2AE-0E17BEDE8ED4Q33889941-666C2B85-5BA3-4CA9-A8BB-A070B2260465Q34471142-8A8DF640-4A40-4EB0-9FBD-18966BA1106CQ34547464-5D8DA6F5-18E8-43D3-9B62-348FEE3C941AQ34695851-F7D86588-8BBC-4AF7-9726-1A81DFC984EFQ34700576-2981BBCF-5A50-428E-AB34-7504EDFCD490Q34741986-165BEC0E-0D92-44A7-A1EC-555A887563E9Q34742776-BE95C03D-6F79-4021-88D5-440FD042E633Q34766003-B3D6A919-83C0-4B98-B6DD-D1B310E6EEC2Q34804900-65C43B9B-112F-438B-BD60-6809E81B14F9Q35011476-28F40515-55B7-404A-8264-E8FC8BCC20C3Q35101225-962DBD04-C575-4533-AC16-F2201DD2540FQ35731392-2504F479-FA79-449B-BE73-B5FD488853D8Q35874893-DB513196-3C23-499E-A786-07F9C8493CAEQ36171255-99108A85-7D3C-4729-965E-45FEC78ECDC0Q36288699-84FE0A4B-3D8E-49A6-BA50-C15AD0079398Q36455914-DDA82962-055F-4AD2-8103-6CFF2018FDE7Q36596778-A320811A-221B-405E-98CB-A960889A5F04Q36742650-34050CE9-4A02-48D8-9546-F7702BC2D344Q36921672-A1E6BE43-214C-4A02-8E06-BA53EE60CE6FQ36964821-898D6CC8-777F-48B5-B311-41105555429CQ37008652-F6262B94-45C3-4610-9F8E-FFE6C292073CQ37319128-77E2CC4F-F99E-4370-9F98-2FA6E6D7F576Q37348898-CCF71D45-9DF9-4496-B100-E6CABAD97248Q37612158-C9F59214-194B-41E9-AC67-B6A96E5E2A2EQ37679879-FBD551E0-640E-48B5-BA44-5475A45E54B7Q37701264-0872A792-27CA-4A16-AB18-72607DC8FD27Q38050560-51397D8E-E533-4311-85E7-EBD6BC33AA3BQ38130748-5DBCFB0A-8BDD-430C-A1EC-7B1AF27A7A2CQ38218159-DB08EB4E-A22D-4576-A1E7-56B3849C4C38Q38237987-3A321059-DDE8-473E-A63E-DE2013F1FC6AQ38256622-47E9F960-0895-4CD3-9E5A-D782BBA0F5F4Q38262194-83FA052F-1865-4920-BAFF-1423B129A738Q38299766-B208581C-7A0A-49C1-BF0F-1D88C00C730AQ38315029-04BB54EF-8F6F-4DCC-87B9-66450A332258Q38376619-AE3C550E-9DAD-44C3-8978-A0762BB1FBD2Q38592327-FCFB0623-F7CE-49D1-8B88-5599D8EB5647Q38622754-319FC995-CA59-43E0-8362-7FA645BAD0F2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John Wilding
@ast
John Wilding
@en
John Wilding
@es
John Wilding
@nl
John Wilding
@sl
type
label
John Wilding
@ast
John Wilding
@en
John Wilding
@es
John Wilding
@nl
John Wilding
@sl
prefLabel
John Wilding
@ast
John Wilding
@en
John Wilding
@es
John Wilding
@nl
John Wilding
@sl
P1053
A-7106-2008
P106
P21
P31
P3829
P496
0000-0003-2839-8404